Metastatic Hormone Refractory Prostate Cancer Pipeline Review H2 2015

1. Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015 By RnRMarketResearch.com Publisher Name : Global Markets Direct Date: 30-Oct-2015 No. of Pages:374 Single User License: US $2000 Browse more Reports on Diseases & treatment at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment . ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

2. Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015 This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

3. Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015 Companies Discussed/Mentioned in this Research: AB Science SA, AbbVie Inc., Adamis Pharmaceuticals Corporation, Advaxis, Inc., Ambrx, Inc., Amgen Inc., Arrowhead Research Corporation, AstraZeneca Plc, ATLAB Pharma SAS, Bavarian Nordic A/S, BIND Therapeutics, Inc., BoehringerIngelheim GmbH, Bristol-Myers Squibb Company, CellCentric Ltd, CureVac GmbH, DexTech Medical AB, Eli Lilly and Company, Emergent BioSolutions Inc., F. Hoffmann-La Roche Ltd., Genentech, Inc., GenSpera, Inc., GlaxoSmithKline Plc, GTx, Inc., Johnson & Johnson, Karyopharm Therapeutics, Inc., Medivation, Inc., Millennium Pharmaceuticals, Inc., NewLink Genetics Corporation, Novartis AG, Oncogenex Pharmaceuticals, Inc., Oncolytics Biotech Inc., Onyx Pharmaceuticals, Inc., Orion Oyj, Pfizer Inc., Progenics Pharmaceuticals, Inc., Sanofi,Sotioa.s., Sun Pharma Advanced Research Company Ltd., Supratek Pharma Inc., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Tesaro, Inc., Tokai Pharmaceuticals, Inc., TRACON Pharmaceuticals, Inc. and Viralytics Ltd. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

4. Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015 Drugs Profile Discussed in this Research: abiraterone acetate, ABS-001, Adipotide, ADXS-PSA, afuresertib hydrochloride, apatorsen, APC-200, APC-300, ASN-001, ATL-101, AZD-5312, AZD-5363, BI-836845, BMTP-11, cabazitaxel, cabazitaxel, carfilzomib, Cell Therapy to Target PSMA for Metastatic Hormone Refractory Prostate Cancer, crizotinib, custirsen sodium, CV-9103, CVA-21, Dendritic Cell Therapy to Target PSA, PAP, Survivin and hTERT for Metastatic Hormone Refractory Prostate Cancer, docetaxel, docetaxel, emibetuzumab, enzalutamide, erismodegib, ES-414, everolimus, galeterone, GSK-2636771, GTx-758, idasanutlin, indoximod, JNJ-56021927, lirilumab, LY-3022855, LY-3023414, masitinib, mipsagargin, Monoclonal Antibody Drug Conjugate to Inhibit PSMA for GBM and CRPC, MVI-816, navitoclaxdihydrochloride, niraparib, ODM-201, ODM-204, olaparib, olaratumab, ONC-113B, Osteodex, pelareorep, Protein for Prostate Cancer, PSMA ADC, rilimogenegalvacirepvec, rilotumumab, sapanisertib, selinexor, Small Molecule to Antagonize Androgen Receptor for Prostate Cancer, Small Molecules to Antagonize Androgen Receptor for Metastatic Castration Resistant Prostate Cancer, Small Molecules to Antagonize Androgen Receptors for Metastatic Hormone Refractory Prostate Cancer, Small Molecules to Inhibit Bromodomain for Prostate Cancer, Small Molecules to Inhibit Deubiquitinase for Castrate Resistant Prostate Cancer, stapuldencel-t, TAS-3681, TL-118, TRC-105, Vaccine for Prostate Cancer, Vaccine to Target Prostate Specific Antigen for Metastatic Hormone Refractory Prostate Cancer and vandortuzumabvedotin ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

5. Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015 Scope For Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015 • The report provides a snapshot of the global therapeutic landscape of Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities • The report reviews key players involved in the therapeutics development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and enlists all their major and minor projects • The report summarizes all the dormant and discontinued pipeline projects • A review of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages • A detailed assessment of monotherapy and combination therapy pipeline projects • Coverage of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline on the basis of target, MoA, route of administration and molecule type ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

6. Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015 Reasons to Buy: • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage • Develop strategic initiatives by understanding the focus areas of leading companies • Identify and understand important and diverse types of therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline • Devise corrective measures for pipeline projects by understanding Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline depth and focus of Indication therapeutics • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

7. Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015 For more details contact Mr. Ritesh Tiwari :sales@rnrmarketresearch.com/ +18883915441 RnRMarkertResearch RnRMarketResearch.com, an online repository of market  research reports, offers in-depth analysis of over 5000 market segments. RnRMarket Research library has syndicated reports by leading market research  publishers across the globe. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441